2023 National Alzheimer's Summit

Shifting Science into Practice

2023 National Alzheimer's Summit
Groundbreaking research on Alzheimer’s prevention, advancements in early detection and diagnosis, and breakthrough disease-modifying treatments now position doctors, nurses, and other healthcare professionals to help patients and families more than ever before. This year’s National Alzheimer’s Summit brings together international leaders to discuss how to best incorporate these monumental developments into everyday practice to benefit the patients health providers see while continuing to build on the work still being done to end Alzheimer’s.

Miss a session?

Jump down to Sessions
to watch anything you missed.

100+

Interface blocks to build a beautiful, dynamic website.

43,000+

Customers have launched sites with Medium Rare templates.

30+

Responsive pages included with Ollie, to complete your online presence.

2023 National Alzheimer's Summit

Summit Schedule

1:15–1:30 PM ET
1:15–1:30 PM ET
This is some text inside of a div block.
Now Live!

Welcome and State of the Movement – George Vradenburg

View Session
Panel
1:30–2:15 PM ET
1:30–2:15 PM ET
This is some text inside of a div block.
Now Live!

Achieving Equity in Alzheimer's Disease

As Alzheimer’s therapies continue to make great progress, questions remain about how we can ensure equitable access to the right treatments, for the right patients, at the right time. What do we know--and not know--about the etiology of the disease in and the impact of new treatments on minoritized, and especially Black, populations?  Key Question: How do we achieve success with such low rates of racial and ancestral diversity in clinical trials?

View Session
PANEL
2:30–3:15 PM ET
2:30–3:15 PM ET
This is some text inside of a div block.
Now Live!

New Technologies for Early Detection and Diagnosis of Alzheimer’s

Scaling up technologies for early detection of Alzheimer’s pathology and cognitive impairment promises to transform the global response to Alzheimer’s disease. Digital biomarkers and fluid biomarkers (ranging from cerebrospinal fluid to blood) to detect the disease are advancing rapidly in clinical practice and will enable a more simple, timely, and accurate Alzheimer’s diagnosis.  Key Question: What do these tools and technologies mean for patients and their doctors?

View Session
ROUNDTABLE
3:30–4:15 PM ET
3:30–4:15 PM ET
This is some text inside of a div block.
Now Live!

Alzheimer’s Symptoms and Care

The toolkit for treating people living with Alzheimer’s has grown significantly over the past few years, causing providers and health systems to adopt new care and treatment paradigms. This panel will look at high-quality care models and the role of symptomatic treatments for Alzheimer’s patients. Key Question: What should become the standard of care in 2024—and what should excellent care look like?

View Session
CLOSING REMARKS
4:15-4:30 PM ET
4:15-4:30 PM ET
This is some text inside of a div block.
Now Live!

Day 1 Closing Remarks

View Session
KICKOFF
1:00-1:25 PM
ET
Now Live!

Day 2 Kickoff

Learn how one action-oriented family is making an impact on preventing Alzheimer’s. David Dolby, of the Dolby Foundation and Dolby Investments, shares his insights on advancements in the field and how families experiencing the disease can be the moral force of change.

View Session
Featured Speakers
David Dolby, George Vradenburg
David Dolby, George Vradenburg
PANEL
1:30–2:15 PM
ET
Now Live!

Meeting Patient Demand for Alzheimer's Treatment

The treatment of Alzheimer’s continues to improve. As new therapies are approved by the FDA, doctors have more options for their patients, leading to better and more patient-centered care. Ideally, a patient who has a concern about their cognition will see their primary care physician, have the confidence to raise the concern, be screened for potential impairment, and if appropriate be referred to a physician with the skill, experience, and infrastructure to consider this patient for a new Alzheimer’s therapy. Key Question: What steps are leading clinicians and health systems taking to ensure that each Alzheimer’s patient who qualifies gets the right drug and in time to make a difference?

View Session
Featured Speakers
Jeffrey Cummings, Darren Gitelman, Debra Lappin, Ronald Petersen
Jeffrey Cummings, Darren Gitelman, Debra Lappin, Ronald Petersen
PANEL
2:30-3:15 PM
ET
Now Live!

One Size Fits One: Precision Medicine and Alzheimer’s Prevention

Proactive, precision, whole health medicine is the next frontier in healthcare. What does this mean for Alzheimer’s? Learn how advances in technology, lifestyle medicine, and preventive therapeutics help not only prevent chronic conditions like heart disease and diabetes but also maintain cognition into older years. It is never too early to talk about brain health. Key Question: How are the latest approaches and cutting-edge modalities giving health professionals an edge against Alzheimer’s?

View Session
Featured Speakers
Howard Fillit, Miia Kivipelto, Rudolph Tanzi, Wim Van Hecke, John Walker, Julie Wood
Howard Fillit, Miia Kivipelto, Rudolph Tanzi, Wim Van Hecke, John Walker, Julie Wood
FIRESIDE CHAT
3:30-3:45 PM
ET
Now Live!

Fireside Chat with Senator Shelley Moore Capito and George Vradenburg

We talk with a distinguished champion of the Concentrating on High-Value Alzheimer’s Needs to Get to an End (CHANGE) Act about its progress and ramifications. Hear what Sen. Capito thinks needs to happen from a government perspective to equip providers with the tools they need to accurately detect and diagnose Alzheimer’s at its earliest stages.

View Session
Featured Speakers
The Honorable Shelley Moore Capito, George Vradenburg
The Honorable Shelley Moore Capito, George Vradenburg
3:45-4:00 PM
ET
Now Live!

Summit Closing Remarks

View Session
Featured Speakers
Russ Paulsen
Russ Paulsen
Rudolph Tanzi

Rudolph Tanzi

Joseph. P. and Rose F. Kennedy Professor of Neurology, Harvard Medical School; Director, Genetics and Aging Research Unit; Co-Director, McCance Center for Brain Health; Co-Director, Mass General Institute for Neurodegenerative Disease, Massachusetts General Hospital
, PhD
The Honorable Shelley Moore Capito

The Honorable Shelley Moore Capito

United States Senator, West Virginia
Julie Wood

Julie Wood

Senior Vice President for Research, Science, and Health of the Public, American Academy of Family Physicians
, MD, MPH, FAAFP
John Walker

John Walker

Chief Technology Officer and Founder, uMethod Health
, PhD
Miia Kivipelto

Miia Kivipelto

Professor, Senior Geriatrician, Director of Research, Development, Education, and Innovation, Karolinska University
, MD, PhD
Wim Van Hecke

Wim Van Hecke

Founder and CEO, icometrix
, PhD
Suzanne Schindler

Suzanne Schindler

Associate Professor of Neurology, Washington University School of Medicine
, MD, PhD
David Reuben

David Reuben

Director, Multicampus Program in Geriatrics Medicine and Gerontology; Chief, Division of Geriatrics; Archstone Foundation Chair and Professor, David Geffen School of Medicine; Director, Alzheimer’s and Dementia Care Program, University of California, Los Angeles
, MD
Kate Possin

Kate Possin

John Douglas French Foundation Endowed Professor, Global Brain Health Institute; Professor, Memory and Aging Center, University of California, San Francisco
, PhD
Ronald Petersen

Ronald Petersen

Professor of Neurology; Cora Kanow Professor of Alzheimer’s Disease Research; Director, Mayo Alzheimer’s Disease Research Center, Mayo Clinic College of Medicine
, MD, PhD
Walter Koroshetz

Walter Koroshetz

Director, National Institute of Neurological Disorders and Stroke
, MD
Drew Holzapfel

Drew Holzapfel

Executive Director, Global CEO Initiative on Alzheimer’s Disease
Dustin Hammers

Dustin Hammers

Associate Professor, Department of Neurology, Indiana University School of Medicine
, PhD, ABPP(CN)
George Grossberg

George Grossberg

Professor and Director, Geriatric Psychiatry, Saint Louis University School of Medicine
, MD
Darren Gitelman

Darren Gitelman

Director of Cognitive Disorders, Advocate Medical Group (Ill.); Neurosciences Medical Research Director and Senior Medical Director, Advocate Memory Center, Advocate Health Care
, MD, FAAN, FANA
Thomas Fagan Jr.

Thomas Fagan Jr.

Vice President, U.S. Alzheimer’s Disease Commercial, Eisai Inc.
David Dolby

David Dolby

CEO, Dolby Family Ventures
Lisa Barnes

Lisa Barnes

Alla V. and Solomon Jesmer Professor, Rush Alzheimer’s Disease Center, Rush University Medical Center
, PhD
Jeffrey Cummings

Jeffrey Cummings

Joy Chambers-Grundy Professor of Brain Science, Director of the Chambers-Gundy Center for Transformative Neuroscience, and Co-Director of the Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada, Las Vegas
, MD, ScD(HC)
Debra Lappin

Debra Lappin

Senior Strategic Counsel, UsAgainstAlzheimer's
Consuelo Wilkins

Consuelo Wilkins

Professor of Medicine, Senior Vice President and Senior Associate Dean for Health Equity and Inclusive Excellence, Vanderbilt University Medical Center
, MD, MSCI
Howard Fillit

Howard Fillit

Co-Founder and Chief Science Officer, Alzheimer’s Drug Discovery Foundation
, MD
Russ Paulsen

Russ Paulsen

Chief Operating Officer, UsAgainstAlzheimer's
Stephanie Monroe

Stephanie Monroe

Vice President and Senior Advisor, Health Equity, UsAgainstAlzheimer's
George Vradenburg

George Vradenburg

Chairman and Co-Founder, UsAgainstAlzheimer's
Us Against Alzheimers 2023
Turning cutting-edge advancements in prevention, early detection, and treatments into patient-centered action

Sponsors

Thank You to Our Sponsors

Premier Sponsors
BiogenEisaiLillyOtsukaRoche
Platinum Sponsors
ADDFGenetech